Compare STGW & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STGW | IMTX |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2006 | N/A |
| Metric | STGW | IMTX |
|---|---|---|
| Price | $6.89 | $9.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $8.39 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.4M | 503.0K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,909,000,000.00 | N/A |
| Revenue This Year | $13.27 | N/A |
| Revenue Next Year | $4.07 | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $4.29 | $5.05 |
| 52 Week High | $7.52 | $12.41 |
| Indicator | STGW | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.25 | 35.89 |
| Support Level | $4.94 | $8.97 |
| Resistance Level | $7.02 | $10.64 |
| Average True Range (ATR) | 0.31 | 0.54 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 53.94 | 13.63 |
Stagwell Inc is a challenger network using AI to deliver marketing and advertising solutions to its clients. It operates in five reportable segments: Marketing Services, Digital Transformation, Media and Commerce, Communications, and The Marketing Cloud. Maximum revenue is generated from the Marketing Services segment, which offers social media solutions, designs breakthrough brand campaigns, and creates immersive experiential marketing programs and social engagement strategies, helping clients connect with audiences across digital platforms. The various brands operating under this segment include 72 and Sunny, Anomaly, NRG, Harris Insights, TEAM, and Movers & Shaker. Geographically, the company generates maximum revenue from the United States, followed by the UK and other countries.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.